#Inflammatory Bowel Disease market

[marketsndata]

Global Inflammatory Bowel Disease Market Size, Share, Growth and Forecast 2031

Global inflammatory bowel disease market is projected to witness a CAGR of 5.15% during the forecast period 2024-2031, growing from USD 22.07 billion in 2023 to USD 32.98 billion in 2031. The market demand for Inflammatory Bowel Disease is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.

Inflammatory Bowel Disease is a chronic inflammatory condition of the gastrointestinal tract. It includes two types: Ulcerative colitis and Crohn’s disease. Ulcerative colitis causes swelling and sores in the colon and rectum. Moreover, Crohn’s disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and anus. Common inflammatory bowel disease symptoms include abdominal pain, diarrhea (sometimes with blood), weight loss, rectal bleeding, fever, anemia, anxiety and depression. The diagnostic process for IBD involves multiple approaches. Clinicians typically start with a detailed medical history and physical examination. Some of the associated procedures include blood tests to evaluate anemia or inflammation, stool tests to exclude infection, and imaging studies such as CT scans or MRIs. The diagnosis is typically established through endoscopic procedures, namely colonoscopy, which permits direct visualization of the mucosal surfaces of the intestinal tract and tissue samples (biopsies) taken for further examination. For instance, as per a systematic review article published on 17 June 2024, reported that the incidence rate of Ulcerative Colitis and Crohn’s Disease in the European region is approximately 24.3 and 12.7 per 100,000, respectively. The annual incidence rates for Ulcerative Colitis and Crohn’s Disease in North America were reported at 19.2 and 20.2 per 100,000 individuals annually. The incidence of IBD in Asia ranges from 0.5 to 3.4 per 100,000 individuals, signifying the dynamic changing face of this emerging disease condition in the region. Incidence has risen over the past 10–15 years in Korea, Japan, China, Hong Kong, and India. The increase was more impressive in countries adopting a Western industrialized lifestyle.

Increase in the Prevalence of Inflammatory Bowel Disease

The increase in the prevalence of Ulcerative colitis and Crohn’s disease is anticipated to fuel the growth of the inflammatory bowel disease market. Increasing inflammatory bowel disease is now emerging as a public health problem that is increasingly taking over industrialized nations. Several causes exist for the increase in this disease, with one significant cause being lifestyle changes: diets high on processed foods and low in fiber negatively impact health and gut health. In addition, the hygiene hypothesis provides an insight revealing that lower exposure to infections in the childhood period shows increased risk factors for autoimmune diseases, such as IBD. An urgent need to do further research into causes and treatments of IBD is a critical reason for the greater number of diagnosed cases. Public education campaigns are also needed towards communities about IBD for early detection and proper management of the disease. Considering that more people are living with the burden of IBD, managing this chronic illness needs a collective effort by providers, researchers, and policymakers to give better care and support to affected patients. For instance, in April 2024, Takeda Pharmaceutical Company Limited received approval from the U.S. Food and Drug Administration for ENTYVIO (vedolizumab) subcutaneous (SC) administration for the treatment in adults with moderately to severely active Crohn’s disease (CD).

Advancements in the Treatment Options for Inflammatory Bowel Disease

Advancements in the treatment of inflammatory bowel disease include a wide approach to managing this chronic condition, such that patients are offered more effective and targeted therapies. Indeed, biologics, which target inflammatory pathways by specifically targeting cells, pathways, or molecules that contribute to inflammation, have revolutionized the management of this disease, from addressing underlying pathogenic mechanisms to the historical approach of symptom relief. Moreover, biologics like anti-TNF agents and integrin inhibitors have also proven useful in many patients’ induction and maintenance of remission. New small molecules and JAK inhibitors are also emerging as additional alternatives in some cases. Personalized medicine has also advanced the ability of doctors to treat individual patients according to their individual genetic makeup and disease characteristics, thus offering a better chance for positive outcomes. Continued research and clinical trials are discovering additional new therapeutic targets, as well as new combination therapies, promising higher efficacy and safety. For instance, on 19 February 2024, Pfizer Inc. received approval from the European Commission (EC) granting marketing authorization for VELSIPITY (etrasimod) to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or was intolerant to either conventional therapy or a biological agent. VELSIPITY is the first and only advanced oral ulcerative colitis treatment approved for use in patients 16 years of age.

Crohn’s Disease Segment to Dominate the Inflammatory Bowel Disease Market

The Crohn’s disease segment dominates the inflammatory bowel disease market due to the high prevalence and the specific need for treatment. Often, Crohn’s disease affects any part of the gastrointestinal tract and generally causes more severe and varied symptoms than ulcerative colitis does, so its requirements are more complex, thus dictating a wide range of treatment options, including biologics, immunosuppressants, and emerging therapies tailored according to the needs of the individual patient. Other drivers for the growth of this segment include improved diagnosis techniques and increased awareness. Research and clinical studies in Crohn’s disease continue to drive ongoing innovations and therapies that improve patient outcomes significantly, thus driving growth in the market. Also, with healthcare providers seeking more practical treatments for this chronic condition, the Crohn’s disease market is poised to capture a greater share of the inflammatory bowel disease market. For instance, on 18 May 2023, AbbVie Inc. received approval from the U.S. Food and Drug Administration for RINVOQ (upadacitinib) to treat adults with moderate to severely active Crohn’s disease.                                                                                                                          

North America Dominates Inflammatory Bowel Disease Market                          

North America dominates the Inflammatory Bowel Disease (IBD) market, primarily driven by a combination of high prevalence rates, advanced healthcare infrastructure, and significant investment in research and development. The incidences of ulcerative colitis in North America range from 2.2 to 19.2 cases per 100,000 person-years, and Crohn’s disease incidences range from 3.1 to 20.2 cases per 200,000 person-years. In the United States the prevalence of adult ulcerative colitis was 238 per 100,000 population and 201 per 100,000 population with data from a large study based on insurance claims. Inflammatory bowel disease is more prevalent in North America and Europe than in Asia or Africa. The region has a well-established healthcare system that makes it easier to administer new, advanced therapies such as biologics and emerging medications specifically designed to meet the needs of each patient. Well-organized awareness programs and support groups help facilitate earlier diagnosis and optimal management of the disease. For instance, on August 12, 2024, Celltrion USA, Inc. (Celltrion USA) received approval from the Food and Drug Administration for biosimilar adalimumab-aaty. Adalimumab-aaty is approved for the treatment of patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease and Ulcerative colitis. The treatment for self-funded employer plans was available in the U.S. from Costco Specialty Pharmacy on October 1, 2023.

Download Free Sample Report

Future Market Scenario (2024-2031F)

The future market scenario seems promising for the inflammatory bowel disease market, influenced by factors that increase demand and investment in this market. The inflammatory bowel disease market is full of promise with the continuous advancement in research, technology, and options available for treatment. Moving into the future, with an increased understanding of the mechanisms driving IBD, more targeted therapies are emerging, such as biologics and small molecules targeting some of the pathways responsible for inflammation. In addition, the increasing incidence of IBD in emerging markets and globally will increase the patient population, which requires effective management systems. Improved diagnosis and early detection methods will ensure timely interventions, which will be beneficial to the patients and improve their quality of life. Other factors that will drive innovation in the field are stronger investment in research and more collaboration between pharmaceutical companies and academic institutions. For instance, on 4 October 2023, Sanofi and Teva Pharmaceuticals announced a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, the two types of inflammatory bowel disease.

Report Scope

“Inflammatory Bowel Disease Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global inflammatory bowel disease market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/inflammatory-bowel-disease-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[delveinsight12]

Inflammatory Bowel Disease Market expected to rise | Companies- Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, expected to drive market

The Inflammatory Bowel Disease market growth is driven by factors like increase in the prevalence of Inflammatory Bowel Disease, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Inflammatory Bowel Disease market report also offers comprehensive insights into the Inflammatory Bowel Disease market size, share, Inflammatory Bowel Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Inflammatory Bowel Disease market size growth forward. 

Some of the key highlights from the Inflammatory Bowel Disease Market Insights Report:

Several key pharmaceutical companies, including Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, and others, are developing novel products to improve the Inflammatory Bowel Disease treatment outlook. 

The total Inflammatory Bowel Disease market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.

As per DelveInsight analysis, the Inflammatory Bowel Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Inflammatory Bowel Disease Market Landscape

Inflammatory Bowel Disease Overview 

Inflammatory bowel disease (IBD) is a term that describes disorders involving long-standing (chronic) inflammation of tissues in your digestive tract. Types of IBD include: Ulcerative colitis. This condition involves inflammation and sores (ulcers) along the lining of your large intestine (colon) and rectum.

Inflammatory bowel disease (IBD) is a term that describes disorders involving long-standing (chronic) inflammation of tissues in your digestive tract. Types of IBD include:

Ulcerative colitis. This condition involves inflammation and sores (ulcers) along the lining of your large intestine (colon) and rectum.

Crohn's disease. This type of IBD is characterized by inflammation of the lining of your digestive tract, which often can involve the deeper layers of the digestive tract. Crohn's disease most commonly affects the small intestine. However, it can also affect the large intestine and uncommonly, the upper gastrointestinal tract.

Both ulcerative colitis and Crohn's disease usually are characterized by diarrhea, rectal bleeding, abdominal pain, fatigue and weight loss.

For some people, IBD is only a mild illness. For others, it's a debilitating condition that can lead to life-threatening complications.

Inflammatory Bowel Disease Symptoms

Inflammatory bowel disease symptoms vary, depending on the severity of inflammation and where it occurs. Symptoms may range from mild to severe. You are likely to have periods of active illness followed by periods of remission.

Signs and symptoms that are common to both Crohn's disease and ulcerative colitis include:

Diarrhea

Fatigue

Abdominal pain and cramping

Blood in your stool

Reduced appetite

Unintended weight loss

Do you know the treatment paradigms for different countries? Download our Inflammatory Bowel Disease Market Sample Report

Recent breakthrough in the Inflammatory Bowel Disease

FDA approves first oral treatment for moderately to severely active Crohn’s disease: 

FDA has approved Rinvoq (upadacitinib) for adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more tumor necrosis factor blockers. Rinvoq is the first approved oral product available to treat moderately to severely active Crohn’s disease.

Patients should start with 45 mg of Rinvoq once daily for 12 weeks. Following the 12-week period, the recommended maintenance dosage is 15 mg once a day. A maintenance dosage of 30 mg once daily can be considered for patients with refractory, severe, or extensive Crohn’s disease.

Inflammatory Bowel Disease Epidemiology Segmentation 

DelveInsight’s Inflammatory Bowel Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Inflammatory Bowel Disease historical patient pools and forecasted Inflammatory Bowel Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Inflammatory Bowel Disease Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

Inflammatory Bowel Disease Prevalence 

Age-Specific Inflammatory Bowel Disease Prevalence 

Gender-Specific Inflammatory Bowel Disease Prevalence 

Diagnosed and Treatable Cases of Inflammatory Bowel Disease

Visit for more @ Inflammatory Bowel Disease Epidemiological Insights

Inflammatory Bowel Disease Treatment Market 

The Inflammatory Bowel Disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Inflammatory Bowel Disease market trends by analyzing the impact of current Inflammatory Bowel Disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

The most common medications used to treat IBD are antibiotics such as metronidazole and ciprofloxacin; ASA anti-inflammatory drugs such as Asacol, Azulfidine, Colazol, Pentasa, Rowasa and Lialda; steroids, such as prednisone, prednisolone or budesonide, immunomodulators such as Imuran(azathioprine), Purinethol, and methotrexate; biologics, such as REMICADE, HUMIRA, CIMZIA, ENTYVIO, STELARA and XELJANZ, nutritional therapy can be used to induce and maintain remission in Crohn’s disease.

There are various drugs currently being studied for the treatment of IBD. The Key players are Eli Lilly and Company, Gilead, Galapagos, Protagonist Therapeutics, Athos Therapeutics, and others.

According to DelveInsight, the Inflammatory Bowel Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

Inflammatory Bowel Disease Key Companies

Eli Lilly and Company

Gilead

Galapagos

Protagonist Therapeutics

Athos Therapeutics

For more information, visit Inflammatory Bowel Disease Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Inflammatory Bowel Disease Market Report:

10 Years Forecast

7MM Coverage 

Descriptive overview of Inflammatory Bowel Disease, causes, signs and symptoms, diagnosis, treatment

Comprehensive insight into Inflammatory Bowel Disease epidemiology in the 7MM

Inflammatory Bowel Disease marketed and emerging therapies 

Inflammatory Bowel Disease companies

Inflammatory Bowel Disease market drivers and barriers 

Key Questions Answered in the Inflammatory Bowel Disease Market Report 2032:

What was the Inflammatory Bowel Disease market share distribution in 2019, and how would it appear in 2032?

What is the total Inflammatory Bowel Disease market size and the market size by therapy across the 7MM for the study period (2019-32)?

What are the important findings from 7MM, and which country will have the greatest Inflammatory Bowel Disease market size from 2019-32?

During the study period (2019-2032), at what CAGR is the Inflammatory Bowel Disease market projected to expand at 7MM?

Table of Contents:

1 Inflammatory Bowel Disease Market Key Comprehensive Insights 

2 Inflammatory Bowel Disease Market Report Introduction

3 Competitive Intelligence Analysis for Inflammatory Bowel Disease

4 Inflammatory Bowel Disease Market Analysis Overview at a Glance

5 Executive Summary of Inflammatory Bowel Disease

6 Inflammatory Bowel Disease Epidemiology and Market Methodology

7 Inflammatory Bowel Disease Epidemiology and Patient Population

8 Inflammatory Bowel Disease Patient Journey

9 Inflammatory Bowel Disease Treatment Algorithm, Inflammatory Bowel Disease Current Treatment, and Medical Practices

10 Key Endpoints in Inflammatory Bowel Disease Clinical Trials

11 Inflammatory Bowel Disease Marketed Therapies 

12 Inflammatory Bowel Disease Emerging Therapies

13 Inflammatory Bowel Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Inflammatory Bowel Disease

16 Inflammatory Bowel Disease Market Key Opinion Leaders Reviews

18 Inflammatory Bowel Disease Market Drivers

19 Inflammatory Bowel Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Inflammatory Bowel Disease Epidemiology 2032

DelveInsight's "Inflammatory Bowel Disease - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Inflammatory Bowel Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight:

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Contact Us:

Kritika Rehani

krehani@delveinsight.com

+91-9650213330

www.delveinsight.com

[insightfulblogz]

Inflammatory Bowel Disease Drugs Market Demand, Industry News, and Developments Analysis 2032

Inflammatory Bowel Disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic condition characterized by inflammation of the gastrointestinal tract, leading to symptoms such as abdominal pain, diarrhea, and malnutrition. Treatment for IBD aims to reduce inflammation and prevent disease flare-ups. Advances in IBD drugs, including biologics, small molecule inhibitors, and immunosuppressants, are providing better options for patients, improving remission rates, and enhancing quality of life.

The Inflammatory Bowel Disease Drugs Market size was valued at USD 21.15 Billion in 2023 and is expected to reach USD 27.65 Billion By 2031 and grow at a CAGR of 3.47% over the forecast period of 2024-2031.

Future Scope

Future developments in IBD drugs are expected to bring forth treatments with fewer side effects and longer-lasting effects. Precision medicine approaches, where treatment is tailored based on genetic and molecular profiling, hold promise for the next generation of IBD drugs. Additionally, research into microbiome-targeting therapies could open up new avenues for managing IBD at the root cause rather than merely addressing symptoms.

Emerging Trends

A notable trend in IBD treatment is the rise of biologic therapies that target specific pathways involved in the inflammatory response. New classes of drugs, such as Janus kinase (JAK) inhibitors and S1P modulators, are showing effectiveness in cases where conventional therapies have failed. There is also a growing interest in gut microbiota modulation, aiming to restore a healthy balance in the digestive system to reduce IBD symptoms.

Applications

IBD drugs are primarily used to induce and maintain remission in patients with Crohn’s disease and ulcerative colitis. They play a crucial role in minimizing hospitalizations, reducing the need for surgical interventions, and improving overall patient outcomes. Biologics and small molecule inhibitors have become standard treatments in severe IBD cases and are increasingly used as first-line therapies.

Key Points

IBD drugs target the inflammation underlying Crohn’s disease and ulcerative colitis.

Biologic therapies and small molecule inhibitors are expanding treatment options.

Precision medicine is on the rise, tailoring treatments to individual patient needs.

Gut microbiota modulation holds promise for more effective, sustainable IBD management.

Conclusion

Innovations in IBD drug therapies are transforming patient care, offering hope for individuals battling these chronic inflammatory conditions. With new treatments targeting specific inflammatory pathways and the advent of precision medicine, IBD management is moving toward more personalized, effective solutions. These advances not only help patients achieve remission but also offer improved quality of life and reduce the long-term complications associated with IBD.

Read More Details: https://www.snsinsider.com/reports/inflammatory-bowel-disease-drugs-market-2988 

Contact Us:

Akash Anand — Head of Business Development & Strategy

Email: info@snsinsider.com

Phone: +1–415–230–0044 (US) | +91–7798602273 (IND) 

[abhilashnale]

Inflammatory Bowel Disease Treatment Market Global Demand Analysis: Sales Consumption, Business Scenario, and Expert Reviews, Forecast by 2032

The Market Dynamics of the Inflammatory Bowel Disease Treatment

The global Inflammatory Bowel Disease Treatment market has emerged as a critical focal point for businesses, offering a wealth of opportunities and challenges. As industries navigate this complex landscape, understanding the underlying market dynamics becomes crucial for strategic decision-making and growth.

According to Straits Research, the global inflammatory bowel disease treatment market size was valued at USD 20.33 Billion in 2022. It is projected to reach from USD XX Billion in 2023 to USD 27.95 Billion by 2031, growing at a CAGR of 3.6% during the forecast period (2023–2031).

Historically, the Inflammatory Bowel Disease Treatment market has witnessed significant transformations, driven by technological innovations, regulatory changes, and evolving consumer preferences. These shifts have reshaped the market landscape, presenting businesses with new avenues for growth, innovation, and competitiveness.

Note: Our reports are currently under revision. To access the most recent primary and secondary data spanning 2023-2031, inclusive of Cost Module, Business Strategy, and Competitive Landscape insights, please click on ""request free sample report."" Expect the report in your inbox within 24 to 48 hours.

Get Access to a Free Copy of Our Latest Sample Report@https://straitsresearch.com/report/inflammatory-bowel-disease-treatment-market/request-sample

Companies and Manufacturers Covered:

Key market players play a pivotal role in shaping the market narrative. By profiling industry leaders, their strategic initiatives, and competitive positioning, the report offers insights into market dynamics, influencing factors, and growth opportunities. These insights are invaluable for businesses seeking to gain a competitive edge, drive innovation, and capitalize on emerging trends.

AbbVie Inc.

Takeda Pharmaceutical Company Limited

Pfizer Inc

Biogen

Novartis AG, Lilly

UCB S.A.

CELLTRION INC.

Merck & Co., Inc

Johnson & Johnson Services, Inc.

The quantitative analysis accompanying the report offers a decade-long perspective on the market's trajectory. By examining historical data, identifying trends, and forecasting future developments, stakeholders can gain a deeper understanding of market dynamics and make informed decisions.

Buy this Premium Research Report@https://straitsresearch.com/buy-now/inflammatory-bowel-disease-treatment-market

A recent comprehensive analysis provides a detailed overview of the Global Inflammatory Bowel Disease Treatment Market, highlighting key growth drivers, emerging trends, and market dynamics. This report serves as an invaluable resource for businesses, offering insights into the market landscape, competitive positioning, and growth prospects.

Global Regional Outlook:

North America: North America is currently the largest market for Inflammatory Bowel Disease Treatment, accounting for a significant share of the global market.

Asia-Pacific: While the North America leads in market size, Asia-Pacific is emerging as the fastest growing region in the Inflammatory Bowel Disease Treatment market.

Research Methodology

The research methodology employed in curating this report is rigorous and comprehensive. By leveraging both primary and secondary data sources, the report ensures accuracy, reliability, and depth. Through interviews with industry experts, analysis of Inflammatory Bowel Disease Treatment market trends, and examination of key growth drivers, the report offers a holistic view of the market landscape.

Market Segmentation:

By Type

Crohn’s Disease

Ulcerative Colitis

By Drug Class

Aminosalicylates

Corticosteroids

TNF inhibitors

IL inhibitors

Anti-integrin

JAK inhibitors

Others

By Route of Administration

Injectable

Oral

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Ask Here For More Customization Study@https://straitsresearch.com/report/inflammatory-bowel-disease-treatment-market/toc

Report Features:

Actionable market intelligence for strategic decision-making

Comprehensive forecasts spanning 2018to 2031

In-depth growth trend assessments

Segment-specific and regional revenue projections

Competitive analysis and market share insights

Innovative product listings for competitive advantage

Insights into the market implications of COVID-19

Report availability in various formats: PDF, XLS, PPT, and digital dashboards

In conclusion, the global Inflammatory Bowel Disease Treatment market presents a dynamic and evolving landscape for businesses. By understanding market dynamics, leveraging strategic insights, and adopting a proactive approach, businesses can navigate this complex landscape successfully, drive growth, and achieve sustainable success.

Report Customization:

Our report is adaptable to your specific needs. For tailored insights, please reach out to our sales team at sales@straitsresearch.com. Additionally, you can contact our representatives directly at +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.) to discuss your research criteria.

[blogbound]

5 SEO Best Practices for IBD Research

Search Engine Optimization (SEO) is crucial for promoting IBD research. By optimizing your online presence, you can reach a broader audience, including potential participants for IBD clinical trials. Effective SEO practices help ensure that your research and trials are easily discoverable by those who are interested or in need. This increased visibility can significantly enhance recruitment efforts, making it easier to find qualified participants for your studies.

Being visible isn't the only goal of search engine optimization; reaching the appropriate people is. For IBD research, this means reaching individuals who are specifically searching for information related to IBD clinical trials. By strategically incorporating these keywords into your content, you can attract more relevant traffic to your website and increase the chances of recruiting the right participants.

A marketing agency can play a pivotal role in optimizing SEO for IBD research studies. These agencies have the expertise to develop and implement comprehensive SEO strategies tailored to the specific needs of your research. By partnering with such an agency, you can leverage their knowledge and experience to improve your search engine rankings, drive more targeted traffic to your site, and ultimately enhance your recruitment efforts for clinical trials and other IBD-related studies.

1. Keyword Research and Optimization

Keyword research is a fundamental aspect of SEO that involves identifying the specific terms and phrases people use when searching for information online. For IBD research, effective keyword research can help you understand what potential participants are looking for, allowing you to tailor your content to meet their needs. By focusing on the right keywords, you can improve your website's visibility on search engines, making it easier for individuals interested in IBD clinical trial to find your studies.

To identify relevant keywords for IBD research, start by brainstorming terms related to your field. Keywords like "inflammatory bowel disease trial," are likely to be highly relevant. Use keyword research tools, such as Google Keyword Planner or SEMrush, to find additional related terms and to assess the search volume and competition for each keyword. Prioritize keywords that have a high search volume but relatively low competition to maximize your reach.

Integrating these keywords naturally into your website content, blog posts, and meta descriptions is crucial for effective SEO. Ensure that your primary keywords appear in strategic places, such as in headings, subheadings, and the first paragraph of your content. Use variations of your keywords throughout your text to maintain a natural flow and avoid keyword stuffing, which can harm your SEO efforts. Additionally, include these keywords in your meta descriptions and alt text for images to further enhance your site's search engine performance. This approach will help attract more relevant traffic to your site, boosting your chances of recruiting participants for your IBD research studies.

2. High-Quality Content Creation

Creating high-quality, informative content is essential for the success of your SEO strategy. Content that is well-researched, engaging, and relevant not only attracts visitors but also establishes your website as a trusted source of information. For IBD research, providing valuable content can help potential participants understand the importance of your studies and encourage them to take part.

To attract and engage readers, consider writing about recent findings in IBD research, sharing participant stories, or discussing the impact of Janssen clinical trials. These topics can resonate with your audience by offering insights into the latest advancements, personal experiences, and the broader implications of your research. By addressing these areas, you can create content that is both informative and compelling, keeping readers interested and coming back for more.

Regularly updating your content is crucial for maintaining and improving your search engine rankings. Fresh content signals to search engines that your website is active and relevant, which can boost your visibility in search results. Frequent updates also give you more opportunities to incorporate new keywords and address trending topics, attracting more visitors and potential participants to your IBD research studies. Consistent, high-quality content helps build your online presence and fosters a strong connection with your audience.

3. On-Page SEO Best Practices

Implementing essential on-page SEO practices is crucial for enhancing your website's visibility and user experience. Proper use of headings (H1, H2, H3) helps organize your content, making it easier for search engines and readers to understand the structure of your page. Optimizing images with descriptive alt text improves accessibility and provides additional opportunities for keyword integration. Ensuring your website is mobile-friendly is also vital, as a significant portion of users access content via mobile devices, and search engines prioritize mobile-responsive sites.

A clean URL structure is another important aspect of on-page SEO. URLs should be simple, descriptive, and include relevant keywords, which helps search engines index your pages more effectively and improves user navigation. Internal linking is also critical, as it connects related content within your site, helping visitors find more information and encouraging them to spend more time on your site. This practice not only enhances user experience but also distributes link equity across your pages, boosting your overall SEO performance.

Partnering with a New York internet marketing agency can greatly assist with on-page SEO optimization. These agencies have the expertise to audit your current practices, identify areas for improvement, and implement effective strategies tailored to your IBD research needs. By leveraging their knowledge, you can ensure your website follows best practices, ultimately improving your search engine rankings and attracting more qualified participants for your IBD clinical trials.

4. Building Backlinks

Inbound or incoming links, or backlinks, are connections that go from one website to another. They are crucial for SEO because search engines like Google use backlinks as a signal of the credibility and authority of a website. A site with numerous high-quality backlinks is likely to rank higher in search engine results, as these links indicate that the content is valuable and trustworthy.

Acquiring high-quality backlinks requires strategic efforts. Collaborating with other researchers and professionals in your field can result in mutual linking, where both parties benefit from increased visibility. Publishing articles in reputable journals or industry-specific websites also helps, as these platforms are considered authoritative sources. Additionally, engaging with online communities, such as forums or social media groups, can lead to natural backlink opportunities when you share valuable insights and content that others find worth referencing.

A marketing agency can play a pivotal role in building a robust backlink profile. These agencies have the expertise and resources to identify and secure high-quality backlink opportunities that align with your business goals. They can leverage their networks, conduct outreach to relevant websites, and create compelling content that attracts backlinks organically. By partnering with such an agency, businesses can enhance their SEO efforts and achieve better search engine rankings.

5. Utilizing Social Media

Social media plays a crucial role in promoting Inflammatory Bowel Disease (IBD) research and increasing its visibility. Platforms like Facebook, Twitter, LinkedIn, and Instagram allow researchers to reach a broad audience, including patients, healthcare professionals, and potential collaborators. By sharing updates, findings, and educational content about IBD, researchers can raise awareness, foster community engagement, and highlight the importance of their work.

Effectively using social media involves several strategies. Researchers should consistently share informative and relevant content, such as study results, patient stories, and upcoming events. Engaging with the audience through comments, direct messages, and live Q&A sessions helps build a loyal following and encourages interaction. Additionally, using targeted ads and hashtags can attract specific demographics, including potential participants for IBD clinical trials. Creating visually appealing posts and leveraging multimedia, such as videos and infographics, can also enhance engagement.

Integrating social media efforts with SEO strategies can significantly boost traffic to your research site. Sharing links to your website's blog posts, publications, and trial announcements on social media platforms can improve your site's search engine rankings. Using relevant keywords and hashtags ensures that your content is discoverable both on social media and search engines. This holistic approach not only drives more visitors to your site but also enhances the overall visibility and impact of your IBD research.

Key Takeaways on How IBD Research Can Use SEO

The five SEO best practices discussed in the blog include optimizing website content with relevant keywords, building high-quality backlinks, creating engaging and informative content, leveraging social media for promotion, and continuously analyzing and improving SEO performance. These strategies collectively enhance your online presence, making it easier for search engines to find and rank your content, thereby increasing visibility and reach.

Implementing these SEO practices offers significant benefits for promoting IBD research. By enhancing your online visibility, you can attract a broader audience, including potential study participants, healthcare professionals, and collaborators. High search engine rankings help establish credibility and authority in the field, while engaging content and active social media presence foster a supportive community around your research.

To maximize the impact of these SEO efforts, consider partnering with a marketing agency. Such agencies possess the expertise and resources to optimize your SEO strategy effectively, ensuring that your IBD research gains the visibility it deserves. By collaborating with professionals, you can successfully recruit participants for your trials and advance the understanding and treatment of inflammatory bowel disease.

[chetanagp]

Inflammatory Bowel Disease Treatment Market size is expected to grow at a CAGR of 7.9% during the forecast period and the market size is expected to reach nearly US$ 34.67 Bn. by 2029.

[covid-safer-hotties]

I loved my teaching career. COVID normalization stole it from me - Published Aug 23, 2024

It might not have been the most favourable, but one of the most memorable comments I ever received on a student evaluation was that I could be “a bit hard to follow, but that was more an example of [my] passion for this subject over anything.” That subject was creative writing. And yes, sometimes, I had difficulty tempering my excitement throughout a teaching career that has now been cut short.

I have – or had – been teaching as a contract or “sessional” creative-writing instructor. Given the competitiveness of the academic job market and my age (I was nearly 40 when I earned the requisite degree, though I had already published four books), I had come to accept that it was unlikely that I would ever have a faculty position. But I could live with that because I still had the rare privilege of making a (barely) livable wage doing something I was very passionate about.

The COVID-19 pandemic took that from me. Actually, that’s not quite right. It was the perceived “end” of the pandemic that really ruined my teaching career.

I am immunocompromised and rely on medication to manage an autoimmune disease. This means vaccine protection from the virus is probably less effective for me than for most people. Also, my particular illness – Crohn’s, an inflammatory bowel disease – has been shown to put me at significantly greater risk than most for long COVID: a potentially chronic condition that can be very debilitating. And despite how it may seem, COVID circulates widely much of the year: We are still in a pandemic.

When universities returned to in-person learning in early 2022, a brief letter from my specialist was all I needed – because of my medical condition – to continue teaching online. But all that changed about a year ago.

Ironically, it is now harder for me to receive accommodation to teach online even though there is less protection in the classroom against COVID. I cannot require masking, which is perhaps our best tool against transmission (particularly respirator-style masks such as N95s), in the classroom. Nor does one-way masking offer as much protection as universal masking. Also, current air filtration in classrooms is generally insufficient. In other words, classrooms are not safe and accessible workplaces for medically vulnerable people. But that’s certainly not how university administrators, and even those who were supposed to represent employees’ interests, perceive things these days.

Last year, trying to discourage me from requesting to teach online, a union rep told me that he “believed in in-person learning.” The most frustrating thing about this comment, and the widely held opinion it represents, is that I too very much miss teaching in person and would, if it were safe to do so. (That said, I believe I am every bit as effective a teacher online.)

On another occasion, a university administrator, after I had submitted my medical documentation, thought “the solution” was for me to co-teach the class so it could include an in-person component and, consequently, less pay for me. After a struggle that went on for months, I taught the class entirely online, but the accommodation agreement I had to sign stated I had “a medical condition that needs limited exposure to as many people as possible.” I nearly refused to put my name to this bizarre description of what is a prevalent disease, but it was too late to apply elsewhere.

It is clear it will only become increasingly difficult for me to teach online as time goes on. The back-and-forth with administrators, department heads and union reps, waiting to find out if I will or won’t be accommodated, and/or what new obstacles will be thrown at me – it has all caused me significant anxiety, which in turn has made it more difficult, ironically, to manage the symptoms of my illness.

I know that the people I have been sparring with are, for the most part, decent folks: They are just ill informed. But I can’t keep trying to do the job of a public-health official to ensure my own health. It’s quite literally making me sick. I’m done. I quit. I have to.

Disability activists have fought long and hard for workplace accessibility to be a right. But the culture has not caught up to understanding the particular accessibility needs of the immunocompromised.

I do not know how to go forward from here. Online courses, especially creative writing, are few and far between. I am looking for online work that utilizes my skills and education and/or that pays more than minimum wage. I have yet to find even an opening for anything like that. For now, I’m grieving: In many ways, it’s a full-time job.

The last time I taught in person was the year I graduated from my MFA program – just months before the pandemic began. After the semester had ended, a student asked if we could have a coffee together so that I could offer further guidance on revising a piece of writing that I had told him was of near-publishable quality. And I only say that to students when it’s true. He also, to my surprise, wanted to share a bit of his own constructive criticism for me – about how I could facilitate workshop discussion a little better. I chuckled at his audacity, though later, upon reflection, took his suggestion. But mostly we focused on his creative work.

As we were getting ready to go our separate ways, he mentioned, in passing, that he had a long drive home: 2½ hours. It has always stayed with me that a student was willing to spend five hours driving for a relatively brief chat over a coffee. Clearly, he thought I was a good teacher, but with more practice and experience, I could become – like a talented, but novice, student writer – an excellent one. Unfortunately, it doesn’t seem like I will get that chance.

[flock-of-cassowaries]

Fun fact, cats can be prescribed low-dose spironolactone for gender dysphoria restrictive cardiomyopathy.

Spironolactone - or, at least, the specific generic preparation of spiro my local human pharmacy carried - tastes like mint.

And I know this, because when I split the 50mg tablets into quarters for my 7 kg ball of furry genetic failure, the smell was strong. And delicious. To me.

My cat cat felt otherwise. We persevered, because he was an absolute sweetheart who accepted me sticking pills down his throat twice a day for years, but you could tell he did not enjoy the mint.

[ Potentially very helpful info for guardians of chronically-ill pets below the cut. ]

Many veterinary drugs are human drugs, and, it’s a lot cheaper - in Canada, at least - to pay out of pocket for them at your local human pharmacy than to purchase them from your vet. Like, orders of magnitude cheaper. Like, iirc, $15 vs. $175 -type cheaper.

And, in Canada at least, your loca human pharmacy will fill these prescriptions; like, this isn’t some sketchy online thing - a real pharmacist at Shopper’s Drug Mart / Rexall / Jean Coutu / Walmart will literally fill a prescription for a cat. Like, nbd, you just give it to them, say “Yeah, it’s for a cat,” and they’re like “Cool, that’ll be 30 minutes.”

And then you get a pill bottle with, like, Nacho Cheese Johnson printed on the label, which is hilarious. (This is a time when you really want to have given your cat an extremely silly name; like, if you’ve named your cat “Dave”, that’s cool, love the Kids In The Hall reference; but you have missed an opportunity here.)

The main issue is that human formulation tend to be much stronger than cat formulations - because humans are enormous - and some drugs come in formats - i.e. caplets - that cannot be safely divided.

Hence, I could get both insulin and spiro from the human pharmacy and divide it to an appropriate dosage for a 7kg cat, but not gabapentin (a caplet, whose minimum human dosage proved to be enough to cause even my objectively-very large cat to fall asleep in his food bowl).

My vet was awesome, and suggested this. The local Walmart pharmacy where I got my own antidepressants happily filled the prescriptions my vet wrote for my sick cat, and this made it financially possible for me to give him the medical care he needed to live with decent quality of life for four more years after his heart condition / diabetes / inflammatory bowel disease was diagnosed (all at once, when he got super-acutely ill; fun summer that was), rather than the six months the emergency vet predicted at the time.

There are some drugs that never get approved for human use, but are available for veterinary use; you will have to get those from your vet.

For example, my cat was on another heart medication - in addition to the spiro - that was not ever marketed for humans in Canada (but, curiously, was marketed for human use in Japan 🤷🏻‍♀️), so I had to get that one as the cat-preparation from the vet, and it was fucking pricey, unfortunately.

But still - it was super-helpful to be able to get the other drugs from a people pharmacy.

Also, for anyone in the Ottawa area with a sick cat / dog / etc. - free to DM for the name of my vet. He was great.

[credenceresearchdotblog]

The Human Microbiome Market is projected to grow from USD 910 million in 2024 to an estimated USD 3060.33 million by 2032, with a compound annual growth rate (CAGR) of 16.37% from 2024 to 2032.The human microbiome market is witnessing rapid growth, driven by advancements in healthcare, biotechnology, and a growing understanding of the critical role microorganisms play in human health. The human microbiome, a collection of microorganisms living in and on the human body, has become a focal point for research and innovation, promising to revolutionize personalized medicine, diagnostics, and therapeutics. The human microbiome comprises trillions of microorganisms, including bacteria, fungi, viruses, and archaea, residing in various parts of the body, such as the gut, skin, oral cavity, and respiratory tract. Among these, the gut microbiome has garnered the most attention due to its profound impact on digestion, immunity, and mental health. Disruptions in the microbiome, known as dysbiosis, have been linked to conditions ranging from inflammatory bowel disease (IBD) and obesity to depression and cancer.

Browse the full report at https://www.credenceresearch.com/report/human-microbiome-market

Market Overview

The global human microbiome market is projected to grow significantly, with a compound annual growth rate (CAGR) exceeding 20% over the next decade. The market encompasses several segments, including probiotics, prebiotics, diagnostic tests, therapeutic solutions, and research tools.

Key drivers for this growth include:

Increased Awareness: Public and professional awareness about the importance of a balanced microbiome has surged. Consumers are increasingly seeking probiotic and prebiotic products to support gut health.

Advancements in Genomics: Technological advancements, such as next-generation sequencing (NGS), have enabled deeper insights into the human microbiome, fueling research and development in this field.

Rising Prevalence of Chronic Diseases: With a growing number of people suffering from lifestyle-related and autoimmune diseases, microbiome-based interventions offer potential therapeutic solutions.

Personalized Medicine: The ability to tailor treatments based on an individual's microbiome composition is becoming a cornerstone of precision medicine.

Key Applications in the Market

Probiotics and Prebiotics: Probiotic products, such as yogurts, capsules, and supplements, have become mainstream, supported by evidence linking them to improved gut health and immunity. Prebiotics, the dietary fibers that nourish beneficial gut bacteria, are also gaining popularity.

Therapeutics: Microbiome-based therapies are being developed for a range of diseases. For instance, fecal microbiota transplantation (FMT) has shown effectiveness in treating Clostridioides difficile infections, while emerging therapies target conditions like diabetes, cancer, and neurological disorders.

Diagnostics: Microbiome diagnostics is an emerging segment focusing on identifying microbiome imbalances and disease markers. Companies are developing kits and services that analyze an individual’s microbiome composition for health insights.

Research and Development: Pharmaceutical and biotech companies are investing heavily in microbiome research to identify novel drug targets and validate microbiome-based interventions.

Challenges and Opportunities

Despite its promising outlook, the human microbiome market faces several challenges:

Scientific Complexity: The microbiome is highly complex, and understanding its interactions with the human body is still in its infancy.

Regulatory Hurdles: Regulatory frameworks for microbiome-based products and therapies are evolving, often delaying product approvals.

Market Competition: The market is becoming crowded with startups and established companies, making differentiation a challenge.

However, these challenges also present opportunities:

Collaborations: Partnerships between academia, biotech firms, and pharmaceutical companies can accelerate research and development.

Innovation: Advances in artificial intelligence (AI) and machine learning can facilitate the analysis of microbiome data, paving the way for breakthroughs.

Future Outlook

The human microbiome market holds immense potential to transform healthcare. As research deepens, products and therapies targeting specific microbiome-related conditions will become more sophisticated and accessible. Investments in this field are likely to yield high returns, given the growing demand for personalized and preventive healthcare solutions.

Key Player Analysis:

4D Pharma

AOBiome

Du Pont De Nemours and Co.

Enterome Biosciences SA

Ferring Pharmaceuticals

Metabiomics Corp. (BioSpherex LLC)

Microbiome Therapeutics LLC

Osel, Inc.

Rebiotix, Inc.

Second Genome

Seres Therapeutics

Synthetic Biologics, Inc.

Vedanta Biosciences

Yakult Honsha Co.

Segmentation:

By Product

Probiotics

Prebiotics

Medical Foods

Supplements

Others

By Disease

Infectious

Endocrine

Metabolic

By Application

Therapeutics

Diagnostics

By Type

FMT

Peptide

Live Biotherapeutic Product

Others

By Regional

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/human-microbiome-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

[tumbrl1]

Butyric Acid Market Potential: Emerging Trends and Applications

Butyric acid, a short-chain fatty acid, is emerging as a significant compound across various industries, driven by its versatile applications in food, pharmaceuticals, agriculture, and chemicals. With growing consumer awareness about health and wellness, and the increasing need for sustainable solutions, the potential for butyric acid in the market is vast. In this article, we explore the untapped opportunities in the butyric acid market and analyze the factors contributing to its rapid growth.

Key Market Drivers

Several factors are driving the growing demand for butyric acid across diverse sectors:

Rising Demand in Animal Feed: Butyric acid has proven benefits as a gut health promoter in livestock, particularly in poultry, swine, and cattle. By enhancing nutrient absorption and improving gut flora, butyric acid helps reduce the use of antibiotics in animal feed, aligning with growing trends for sustainable and healthier agricultural practices. As global meat consumption rises, the demand for butyric acid in animal feed is expected to surge.

Growth of the Functional Food Market: Butyric acid plays a vital role in promoting digestive health by supporting gut microbiota. The increasing focus on preventive healthcare and gut health has led to a surge in demand for functional foods that contain butyric acid. This trend is contributing significantly to the market’s potential, especially as more consumers embrace a health-conscious lifestyle. Butyric acid is increasingly being used in dietary supplements targeting digestive issues and overall wellness.

Pharmaceutical Applications: Butyric acid is gaining attention in the pharmaceutical sector due to its anti-inflammatory properties and potential therapeutic applications. It has shown promise in the treatment of chronic gastrointestinal conditions such as Inflammatory Bowel Disease (IBD), irritable bowel syndrome (IBS), and other inflammatory disorders. Research into its potential as a treatment for metabolic diseases and cancer is opening up new opportunities for butyric acid in the pharmaceutical market.

Technological Advancements: Innovations in biotechnology, particularly fermentation technology, are improving the efficiency and scalability of butyric acid production. These advances are reducing production costs, making butyric acid more affordable and accessible. As the process becomes more cost-effective, demand is likely to rise in various applications, from food to pharmaceuticals.

Emerging Applications and Innovations

As new research uncovers the benefits of butyric acid, more applications are emerging across multiple industries. In the food sector, butyric acid is increasingly being used as a flavoring agent, contributing to the distinctive flavor of dairy products like cheese and butter. Additionally, it’s being explored as a preservative in processed foods, providing an alternative to artificial additives.

Butyric acid is also being studied for its potential use in the cosmetic and personal care industries. Research is ongoing into its role in skin health, as it has shown potential as a natural anti-inflammatory agent in skincare formulations.

Moreover, in agriculture, the demand for more eco-friendly and sustainable practices is driving the use of butyric acid as a feed additive that promotes better animal health while reducing the environmental impact of livestock farming.

Geographic Market Potential

Geographically, the butyric acid market has strong growth potential in emerging economies, particularly in Asia-Pacific, Latin America, and Africa. In these regions, the expanding agricultural industry, coupled with the rising consumption of processed foods, presents a significant opportunity for butyric acid producers. The rising middle class, urbanization, and increasing awareness about health are expected to drive the demand for functional foods, dietary supplements, and animal feed, which are the primary drivers of butyric acid consumption.

North America and Europe remain the largest markets for butyric acid, driven by established industries in pharmaceuticals, food, and agriculture. However, the rapid growth in health-consciousness and demand for organic and sustainable products in emerging markets presents untapped potential for market expansion.

Challenges and Market Constraints

Despite the promising potential, the butyric acid market faces challenges that may hinder its growth. High production costs, particularly in fermentation-based methods, remain a major constraint. While technological advancements are helping reduce costs, the commercial-scale production of butyric acid still requires significant investment.

Additionally, regulatory hurdles in various regions could delay the widespread use of butyric acid in food and pharmaceutical products. Companies will need to navigate complex regulatory landscapes to ensure that products meet safety and quality standards.

Conclusion

The butyric acid market is poised for significant growth due to its expanding applications in animal feed, food, pharmaceuticals, and agriculture. With increasing consumer demand for health-focused products, innovations in production technology, and the growing emphasis on sustainable practices, the potential for butyric acid in the market is immense. Companies that invest in research and development, explore new applications, and improve production efficiency are well-positioned to capitalize on the growing demand for this versatile compound.

Get Free Sample and ToC : https://www.pristinemarketinsights.com/get-free-sample-and-toc?rprtdtid=NDcy&RD=Butyric-Acid-Market-Report

[marketsndata]

Global Gastrointestinal Drugs Market Size, Share, Growth and Forecast 2031

Global gastrointestinal drugs market is projected to witness a CAGR of 4.23% during the forecast period 2024-2031, growing from USD 45.20 billion in 2023 to USD 62.96 billion in 2031. The market’s growth is boosted by the rising cases of gastrointestinal diseases, novel product launches by the market players, and increasing emphasis on ensuring the availability of gastrointestinal drugs in different regions across the globe.

Technological advancements in drug delivery mechanisms and formulations are enhancing the efficacy of gastrointestinal drugs. The advancements include the development of extended-release and delayed-release formulations that aid in improving the bioavailability and absorption of the drugs, resulting in improved patient outcomes. Such developments are revolutionizing the treatment of ulcerative colitis and Crohn’s disease, among others, providing lucrative growth opportunities for the market.

The rising prevalence of various gastrointestinal disorders, such as celiac disease, is also propelling the growth of the global gastrointestinal drugs market. According to an article published in the StatPearls journal of StatPearls Publishing LLC in August 2023, the prevalence of celiac disease is approximately 0.5% to 1% among the general population. Additionally, the number of cases of Crohn’s disease is also increasing at a rapid rate. According to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, more than half a million people are suffering from Crohn’s disease in the United States. Thus, various pharmaceutical companies are investing in research activities to augment the development of novel therapies to combat the growing threat of Crohn’s disease. In October 2023, Eli Lilly and Company announced that the investigational interleukin-23p19 antagonist, mirikizumab met all major secondary and co-primary endpoints in a phase 3 study, evaluating its efficacy and safety for treating adults with severely to moderately active Crohn’s disease. 

Increasing Cases of Gastrointestinal Diseases Boost Market Demand

The rising cases of gastrointestinal distress in various regions across the globe due to changes in lifestyle and eating habits of the population is one of the major factors bolstering the global gastrointestinal drugs market demand. Factors such as increased stress and the rising prevalence of obesity are also propelling the incidences of gastrointestinal diseases. According to the estimates of the World Health Organization (WHO), 1 in 8 people around the world were living with obesity in 2022. This increase is augmenting the incidences of diseases such as peptic ulcers, irritable bowel syndrome, and gastroesophageal reflux disease. Furthermore, the rapid expansion of the aging population is also boosting the demand for gastrointestinal drugs as the older population is more susceptible to gastrointestinal issues. The WHO estimates that approximately 1 in 6 people across the globe will be 60 or older by 2030. Due to the rising occurrences of such issues, pharmaceutical companies are also increasingly focusing on developing innovative therapies that address the underlying cause of the disease rather than alleviating symptoms.

Rising Efforts of Pharma Companies Supports Market Expansion

The rising efforts of the key players in the market to ensure the availability of novel gastrointestinal drugs through investments and partnerships is boosting the global gastrointestinal drugs market size. In June 2024, AbbVie Inc. secured its position in the gastrointestinal drugs market by paying USD 150 million to China-based FutureGen Biopharmaceutical (Beijing) Co., Ltd. in near-term fees for rights to antibody drug targeting TL1A molecule that has been linked with a heightened immune response in cases of inflammatory bowel disease.

Similarly, in June 2024, Akum Drugs and Pharmaceuticals Ltd. unveiled new formulations for gastrointestinal diseases for patients in India. The company’s Rabeprazole + Levosulpiride SR Capsules received approval from the Drug Controller General of India (DCGI). The drugs aim to provide relief to patients suffering from gastrointestinal tract disorders. Rabeprazole sodium, a potent antisecretory compound, has demonstrated efficacy in treating duodenal and gastric ulcers along with gastroesophageal reflux disease by selectively inhibiting the secretion of gastric acid. Such efforts are expected to aid patients suffering from gastrointestinal issues in effectively managing their conditions and provide lucrative growth opportunities to the gastrointestinal drug market. 

Retail Pharmacies Hold Significant Market Share

The segment’s expansion can be attributed to the rising requirement for over-the-counter (OTC) gastrointestinal drugs over the past few years due to the rising cases of gastrointestinal distress and consumer preference for immediate relief from common digestive issues, including constipation, acid reflux, diarrhea, and heartburn. As per the American College of Gastroenterology (ACG) estimates, approximately 20% of the population of the United States suffers from gastroesophageal reflux disease. Due to the widespread presence of retail pharmacies and their convenient nature, patients suffering from gastrointestinal issues prefer them for purchasing medication, especially in semi-urban and urban locations.

Meanwhile, online pharmacies are expected to grow rapidly over the next few years due to the growing preference for online shopping, fast delivery, shipping, and the availability of lucrative discounts. Other advantages online pharmacies offer include increased consumer accessibility to a broad range of products. Additionally, the growing popularity of digital consultation and the rising availability of e-prescriptions have also made it easier for patients to avail themselves of the required medications through online pharmacies, bolstering the segment’s growth. 

North America Holds Major Market Share

The growth of the North American gastrointestinal drugs market can be attributed to the increasing efforts of the leading market players based in the region to ensure novel product launches, rising cases of gastrointestinal diseases, and the presence of well-established healthcare and pharmaceutical sectors. Various gastrointestinal diseases, including ulcerative colitis, Crohn’s disease, and inflammatory bowel disease, are becoming increasingly prevalent in the United States, bolstering the market’s demand. As per the estimates of the US Centers for Disease Control and Prevention, the prevalence of inflammatory bowel disease is between 2.4 and 3.1 million in the United States, with differing burdens across groups. Additionally, the prominent presence of various research organizations that are increasingly focusing on investigating different gastrointestinal diseases is also expected to influence the market’s expansion positively. Moreover, the increasing availability of novel drugs due to the increasing provision of approvals by the regulatory bodies in the region is also supporting the market’s growth is the region. In 2023, the US Food and Drug Administration (FDA) provided approval to five new gastrointestinal targeted drugs, including colonoscopy prep, inflammatory bowel disease, and gastroesophageal reflux disease. Such approvals are expected to increase the influx of various gastrointestinal drugs in North America.

Download Free Sample Report

Future Market Scenario (2024-2031F)

As per the global gastrointestinal drugs market analysis, the market is expected to witness significant growth in the coming years due to the growing burden of different gastrointestinal diseases and the increasing efforts of the market players towards novel product launches. According to an article published in January 2024 in the Dovepress of the Dove Medical Press Ltd, the prevalence of Crohn’s disease is expected to increase to 1% in 2030 in Western European countries and the United States. This increase will bolster the market’s demand to meet the growing drug requirement for effective management and treatment of the condition. The cases of gastrointestinal distress are also expected to increase in the coming years due to the increasing preference for fast foods and dining out as a fast food-filled diet lacks essential fiber intake, resulting in decreased adoption of water.

Additionally, the market is also expected to witness significant growth over the forecast period due to the rising investments by the leading pharmaceutical companies towards research and development activities and the emphasis on creating targeted therapies that provide minimal side effects along with long-term relief. Furthermore, the growing efforts of various countries to enhance their healthcare sectors and ensure the availability of necessary therapies and treatment solutions are further expected to propel the global gastrointestinal drugs market growth. 

Report Scope

“Gastrointestinal Drugs Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gastrointestinal drugs market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/gastrointestinal-drugs-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[aarunresearcher]

United States endoscopy devices market size reached USD 11.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 21 Billion by 2033, exhibiting a growth rate (CAGR) of 6.8% during 2025-2033. The rising incidence of gastrointestinal diseases, such as colorectal cancer, inflammatory bowel disease, and gastroesophageal reflux disease, which has led to an increased demand for endoscopic procedures for both diagnosis and treatment, is driving the market.